Physician profile
Diana E Clabots
NPI 1689295792
$1,143.02
in general payments reported to CMS, 2019-2025
12 companies · $630 in 2025
The $630 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.86 · 2021: $57.12 · 2022: $17.58 · 2023: $125 · 2024: $300 · 2025: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,054.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,054.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $473.95 | 2023-2025 | Dovato, Cabenuva, Rukobia |
| Gilead Sciences, INC. | $190.71 | 2021-2025 | |
| Shionogi INC | $144.60 | 2023-2025 | Fetroja |
| Abbvie INC. | $110.50 | 2025 | |
| Astellas Pharma US INC | $50.12 | 2024 | Cresemba |
| Astrazeneca Pharmaceuticals LP | $41.04 | 2020-2021 | |
| Theratechnologies INC. | $32.29 | 2025 | Trogarzo |
| Insmed, INC. | $26.53 | 2025 | Brinsupri, Arikayce |
| Aimmune Therapeutics, INC. | $22.73 | 2024 | |
| Cumberland Pharmaceuticals, INC. | $19.41 | 2025 | Vibativ |
| Alvogen INC | $17.58 | 2022 | |
| Merck Sharp & Dohme LLC | $13.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Clabots listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.